Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-13
2010-06-29
Andres, Janet L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S330000
Reexamination Certificate
active
07745468
ABSTRACT:
The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.
REFERENCES:
patent: 4999357 (1991-03-01), Gadras et al.
patent: 5196446 (1993-03-01), Levitzki et al.
patent: 5700822 (1997-12-01), Hirth et al.
patent: 5773476 (1998-06-01), Chen et al.
patent: 5854285 (1998-12-01), Sriram et al.
patent: 5981569 (1999-11-01), App et al.
patent: 6194453 (2001-02-01), Sriram et al.
patent: 6225346 (2001-05-01), Tang et al.
patent: 6331555 (2001-12-01), Hirth et al.
patent: 6420338 (2002-07-01), Schneider et al.
patent: 6426366 (2002-07-01), Novogrodsky et al.
patent: 6433018 (2002-08-01), Siddiqui et al.
patent: 6555702 (2003-04-01), Sriram et al.
patent: 6596828 (2003-07-01), Kaito et al.
patent: 6596878 (2003-07-01), Chen et al.
patent: 2002/0045191 (2002-04-01), Schneider et al.
patent: 2002/0115714 (2002-08-01), Sriram et al.
patent: 2003/0013748 (2003-01-01), Novogrodsky et al.
patent: 2003/0032596 (2003-02-01), Schneider et al.
patent: 2007/0232668 (2007-10-01), Priebe et al.
patent: 2555789 (1977-07-01), None
patent: WO 91/16305 (1991-10-01), None
patent: WO 95/14464 (1995-01-01), None
patent: WO 95/24190 (1995-09-01), None
patent: WO 98/06391 (1998-02-01), None
patent: WO 2005/058829 (2005-06-01), None
patent: WO 99/05109 (2009-02-01), None
1994:457456 Hcaplus Abstract, Journal of Heterocyclic Chemistry, 31, 329, pp. 329-331, “Reaction of Emaminonitriles with Isocyanates. Synthesis of New 2-Oxo and 6-oxopyrimadines”, Cocco et. al.
Hcaplus 1998:545399.
Hcaplus 2005:246273.
Levitzki, Alexander, “Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction”, The FASEB Journal, vol. 6, Nov. 1992, pp. 3275-3282.
Alas and Bonavida, “Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis,”Clin. Cancer Res., 9(1):316-26, 2003.
Alcon et al, “Activation of Tyrosine Kinase Pathway by Vanadate in Gallbladder Smooth Muscle,”Biochem. Pharmacol., 59:1077-1089, 2000.
Arbel et al., “Inhibitors that target protein kinases for the treatment of ovarian carcinoma,”Am. J. Obstet. Gynecol., 188(5):1283-90, 2003.
Bharti et al., “Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells,”J. Immunol., 171(7):3863-3871, 2003.
Burdelya et al, “Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone,”Mol. Cancer Ther., 1(11):893-9, 2002.
Catlett-Falcone et al., “Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells,”Immunity, 10(1):105-15, 1999.
Constantin et al., “Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis,”Eur. J. Immunol., 28(11):3523-9, 1998.
De Vos et al., “JAK2 tyrosine kinase inhibitor tyrphostin AG490 down regulates the mitogen-activated protein kinase (MAPK) and signal trasducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells,”Br. J. Haematol. 109:823-828, 2000.
Gazit et al., “Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenomalononitrile tyrphostins as potent inhibitors of EG receptor and ErbB2
ue tyrosine kinases,”J. Med. Chem., 34(6):1896-1907, 1991.
Gazit, et al, “Tyrphostins I; synthesis and biological activity of protein tyrosine kinase inhibitors,”J. Med. Chem., 32:2344-2352, 1989.
Hallek et al., “Multiple myeloma: increasing evidence for a multistep transformation process,”Blood, 91(1):3-21, 1998.
Hideshima et al., “NF-kappa B as a therapeutic target in multiple myeloma,”J. Biol. Chem., 277(19):16639-16647, 2002.
Jernberg-Wiklund et al, “Expression of myc-family genes in established human multiple myeloma cell lines: L-myc but not c-myc gene expression in the U-266 myeloma cell line,”Int. J. Cancer, 51(1):116-123, 1992.
Kerr et al., “Of JAKs, STATs, blind watchmakers, jeeps and trains,”FEBS Lett., 546(1):1-5, 2003.
Kirken et al., “Tyrphostin AG0490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells,”J.Leukoc. Biol., 65:891-899, 1999.
Kuehl et al., “Dysregulation of c-myc in multiple myeloma,”Curr. Top Microbial. Immunol., 224:277-282, 1997.
Levitzki et al., “Tyrosine phosphorylation is an obligator event in IL-2 secretion,”Biochem. Pharmacol. 40:913-918, 1990.
Meydan et al, “Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor,”Nature379:645-648, 1996.
Renglin et al., “Miotic aberrations induced by carbaryl reflect tyrosine kinase inhibition with coincident up-regulation of serine/threonine protein phosphatase activity: implications for coordination of karyokinesis and cytokinesis,”Mutagenesis. 14(3):327-334, 1999.
Selvanayagam et al., “Alternation and Abnormal Expression of thec-mycOncogene in Human Multiple Myeloma,”Blood, 71(0:30-35, 1988.
Verma et al., “Jak family of kinases in cancer,”Cancer Metastasis Rev., 22(4):423-434, 2003.
Volberg et al, “Disruption of Microtubules in Living Cells by Tyrphostin AG-1714,”Cell Motility and the Cytaskelton, 45(3):223-234; 2000.
Wang et al., “JAK3, STAT, and MAPK signaling pathways as novel molecular target for the tyrphostin AG-490 regulation of IL-2-mediated T cell response,”J. Immunol, 162:3897-3904, 1999.
“Design, Synthesis and Structure-Activity Relationships of Novel Jak2/STAT3 Signaling Inhibitors,” AACR Abtract Later Breaking News, Feb. 1, 2006 (Abstract No. 06-LBA-8902-AACR).
Chen et al., “Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites,”In Vitro, 18(1):24-34, 1982.
Iwamaru et al., “A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo,”Oncogene, 26: 2435-44, 2007.
Lieber et al., “Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas,”Int. J. Cancer, 15(5):741-747, 1975.
Morgan et al., “Human cell line (colo 357) of metastatic pancreatic adenocarcinoma,”Int. J. Cancer, 25(5):591-598, 1980.
Satyamoorthy et al., “Melanoma cell lines from different stages of progression and their biological and molecular analyses,”Melanoma Res., 7(Supp1.2):S35-S42, 1997.
Vezeridis et al., “In vivo selection of a highly metastatic cell line from a human pancreatic carcinoma in the nude mouse,”Cancer, 69(8):2060-2063, 1992.
Vezeridis et al., “Heterogeneity of potential for hematogenous metastasis in a human pancreatic carcinoma,”J. Surg. Res., 48(1):51-55, 1990.
Yu and Jove, “The stats of cancer-new molecular targets come of age,”Nature Rev. Cancer, 4(2):97-105, 2004.
Database CA, Accession No. 96215, 1999.
Database CA, Accession No. 446109, 1976.
Database CA, Accession No. 478235, 1990.
Database CA, Accession No. 584231, 1977.
Database Crossfire Beilstein, Accession No. 9145100.
European Supplementary Search Report, issued in PCT/US2004/041712, dated Oct. 10, 2008.
Tamiz et al., “Structure-Activity Relationship of N- (Phenylalkyl) cinnamides as Novel NR2B Subtype-Selective NMDA Receptor Antagonists,”J. of Medicinal Chemistry, 42 (17): 3412-3420, 1999.
Farooki et al., “Tyrphostins disrupt stress fibers and cellular attachments in endothelial monolayers,”Exp. Cell. Res., 243 (1): 185-198, 1998.
Zlotnik et al., “Tyrphostins reduce chemotherapy-induced intestinal in
Donato Nicholas
Fokt Izabela
Levitzki Alexander
Priebe Waldemar
Szymanski Slawomir
Andres Janet L.
Board of Regents, University of Texas Systems The
Fulbright & Jaworski LLP
Robinson Binta M
LandOfFree
Compounds for treatment of cell proliferative diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for treatment of cell proliferative diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for treatment of cell proliferative diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232418